-
1.发明申请PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING EZETIMIBE 有权制备包含EZETIMIBE的药物组合物的方法公开(公告)号：US20120135976A1
公开(公告)日：2012-05-31
申请号：US13147956
申请日：2010-02-05
申请人： Janez Kerc , Miha Homar , Polona Jurkovic
发明人： Janez Kerc , Miha Homar , Polona Jurkovic
IPC分类号： A61K31/397 , A61P7/00
CPC分类号： A61K9/145 , A61K9/2018 , A61K9/2095
摘要： The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing ezetimibe, comprising the steps of: a) providing a composition comprising ezetimibe, b) sieving a composition comprising a composition of step (a), c) shear mixing of the composition after step (b), preferably the mixing of the composition is carried out by high shear mixing, d) formulation into a dosage form. The present invention also relates to dosage forms containing ezetimibe and ezetimibe and simvastatin, which have been prepared according to the process according to the invention.
摘要翻译： 本发明属于制药工业领域，涉及制备含有依泽替米贝的剂型的方法，该方法包括以下步骤：a）提供包含依泽麦布的组合物，b）筛分包含步骤（a），c ）组合物在步骤（b）之后的剪切混合，优选组合物的混合通过高剪切混合进行，d）配制成剂型。 本发明还涉及根据本发明的方法制备的依泽替米贝，依泽替米贝和辛伐他汀的剂型。
-
2.发明授权Process for the preparation of a pharmaceutical composition comprising ezetimibe 有权制备包含依泽替米贝的药物组合物的方法公开(公告)号：US09089486B2
公开(公告)日：2015-07-28
申请号：US13147956
申请日：2010-02-05
申请人： Janez Kerc , Miha Homar , Polona Jurkovic
发明人： Janez Kerc , Miha Homar , Polona Jurkovic
IPC分类号： A61K9/14 , A61K9/20 , A61K31/366 , A61K31/397 , A61P3/06
CPC分类号： A61K9/145 , A61K9/2018 , A61K9/2095
摘要： The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing ezetimibe, comprising the steps of: a) providing a composition comprising ezetimibe, b) sieving a composition comprising a composition of step (a), c) shear mixing of the composition after step (b), preferably the mixing of the composition is carried out by high shear mixing, d) formulation into a dosage form. The present invention also relates to dosage forms containing ezetimibe and ezetimibe and simvastatin, which have been prepared according to the process according to the invention.
摘要翻译： 本发明属于制药工业领域，涉及制备含有依泽替米贝的剂型的方法，该方法包括以下步骤：a）提供包含依泽麦布的组合物，b）筛分包含步骤（a），c ）组合物在步骤（b）之后的剪切混合，优选组合物的混合通过高剪切混合进行，d）配制成剂型。 本发明还涉及根据本发明的方法制备的依泽替米贝，依泽替米贝和辛伐他汀的剂型。
-
3.发明申请CONTROLLED RELEASE TAMSULOSIN HYDROCHLORIDE TABLETS AND A PROCESS OF MAKING THEM 审中-公开受控释放的羟色胺盐酸盐片及其制备方法公开(公告)号：US20110033534A1
公开(公告)日：2011-02-10
申请号：US12680135
申请日：2008-09-25
申请人： Janez Kerc , Miha Homar , Polona Jurkovic
发明人： Janez Kerc , Miha Homar , Polona Jurkovic
CPC分类号： A61K9/2018 , A61K9/2031 , A61K9/2054 , A61K9/2853 , A61K9/2866 , A61K31/18
摘要： The present invention relates to a controlled release preparation of tamsulosin hydrochloride comprising hydroxypropylcellulose and polyethylene oxide, and the process for making such pharmaceutical composition.
摘要翻译： 本发明涉及包含羟丙基纤维素和聚环氧乙烷的盐酸坦索罗辛的控释制剂及其制备方法。
-
公开(公告)号：US08592490B2
公开(公告)日：2013-11-26
申请号：US12521386
申请日：2007-12-14
申请人： Igor Legen , Janez Kerc , Polona Jurkovic
发明人： Igor Legen , Janez Kerc , Polona Jurkovic
CPC分类号： A61K9/0095 , A61K9/1075 , A61K9/1611 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2054 , A61K9/2095
摘要： Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.
摘要翻译： 用于增强包含聚氧乙烯山梨糖醇酐脂肪酸酯乳化剂的药物成分的溶解度的自微乳化药物递送系统和微乳液; 脂肪酸酯共乳化剂和油。
-
公开(公告)号：US20100331356A1
公开(公告)日：2010-12-30
申请号：US12521386
申请日：2007-12-14
申请人： Igor Legen , Janez Kerc , Polona Jurkovic
发明人： Igor Legen , Janez Kerc , Polona Jurkovic
IPC分类号： A61K31/436 , A61K47/32 , A61K31/415 , A61K31/41 , A61K31/4155 , A61K31/44
CPC分类号： A61K9/0095 , A61K9/1075 , A61K9/1611 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2054 , A61K9/2095
摘要： Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.
摘要翻译： 用于增强包含聚氧乙烯山梨糖醇酐脂肪酸酯乳化剂的药物成分的溶解度的自微乳化药物递送系统和微乳液; 脂肪酸酯共乳化剂和油。
-
公开(公告)号：US20110068497A1
公开(公告)日：2011-03-24
申请号：US12865479
申请日：2009-01-29
CPC分类号： A61K9/5153 , A61K9/1647 , A61K9/1694 , A61K9/5192 , B01J13/04
摘要： A method for preparing nanoparticles is provided, which comprises the steps of dissolving a polymer and, optionally, at least one additional ingredient, in an organic solvent, passing the solution through a vibrating nozzle and dropping the solution through the electrical field into an aqueous solution, which is stirred, such that nanoparticles are formed by the rapid diffusion of the solvent.
摘要翻译： 提供了一种制备纳米颗粒的方法，其包括将聚合物和任选的至少一种另外的成分溶解在有机溶剂中，使溶液通过振动喷嘴并将溶液通过电场滴入水溶液中的步骤 ，其被搅拌，使得通过溶剂的快速扩散形成纳米颗粒。
-
7.发明申请公开(公告)号：US20120027854A1
公开(公告)日：2012-02-02
申请号：US13132055
申请日：2009-11-30
申请人： Miha Homar , Mateja Burjak , Breda Husu-Kovacevic , Janez Kerc
发明人： Miha Homar , Mateja Burjak , Breda Husu-Kovacevic , Janez Kerc
CPC分类号： A61K9/2086 , A61K9/2018 , A61K31/366 , A61K31/397 , A61K2300/00
摘要： The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing simvastatin and ezetimibe, comprising the steps of providing a first composition containing simvastatin, providing a second composition containing ezetimibe, and forming a dosage form comprising at least two separate compartments, wherein one compartment is formed using either the first or the second composition and another compartment is formed using the other composition. The present invention also relates to a process for preparing dosage forms containing simvastatin and ezetimibe, wherein the process involves a direct compression step. Furthermore, the present invention belongs to a dosage form obtained by this process, comprising at least two separate compartments, wherein one compartment contains simvastatin and one compartment contains ezetimibe. Finally, the present invention relates to a combination dosage form comprising a combination of simvastatin and ezetimibe present in two separate compartments of the dosage form.
摘要翻译： 本发明属于制药工业领域，涉及一种制备含有辛伐他汀和依泽替米贝的剂型的方法，包括以下步骤：提供含有辛伐他汀的第一组合物，提供含有依泽替米贝的第二组合物，并形成至少包含 两个独立的隔室，其中使用第一或第二组合物形成一个隔室，并且使用另一个组合物形成另一隔室。 本发明还涉及制备含有辛伐他汀和依泽替米贝的剂型的方法，其中该方法涉及直接压缩步骤。 此外，本发明属于通过该方法获得的剂型，其包含至少两个单独的隔室，其中一个隔室含有辛伐他汀，一个隔室含有依泽替米贝。 最后，本发明涉及包含存在于剂型的两个分开的隔室中的辛伐他汀和依泽替米贝的组合的组合剂型。
-
8.发明申请公开(公告)号：US20110111042A1
公开(公告)日：2011-05-12
申请号：US12989380
申请日：2009-04-21
申请人： Janez Kerc , Miha Homar , Mirjana Gasperlin
发明人： Janez Kerc , Miha Homar , Mirjana Gasperlin
IPC分类号： A61P25/24 , A61K9/16 , A61P25/06 , A61P25/28 , A61P3/10 , A61P31/10 , A61P9/02 , A61P29/00 , A61P25/20
CPC分类号： A61K9/1611 , A61K9/1075 , A61K9/1617 , A61K9/5036 , A61K9/5073
摘要： The invention provides a microcapsule having a shell and a liquid core incorporating a self-microemulsifying system or a microemulsion, wherein the core comprises a lipophilic substance, at least one surfactant, an active agent, a gelling agent and optionally a cosolvent. Furthermore, a method for producing such microcapsules and pharmaceutical formulations comprising such microcapsules is provided.
摘要翻译： 本发明提供一种具有外壳和包含自微乳化体系或微乳液的液芯的微胶囊，其中芯包含亲脂性物质，至少一种表面活性剂，活性剂，胶凝剂和任选的助溶剂。 此外，提供了制备这种微胶囊的方法和包含这种微胶囊的药物制剂。
-
公开(公告)号：US20100172969A1
公开(公告)日：2010-07-08
申请号：US12532130
申请日：2008-03-18
申请人： Rok Dreu , Miha Homar , Mateja Burjak , Janez Kerc , Stanko Srcic
发明人： Rok Dreu , Miha Homar , Mateja Burjak , Janez Kerc , Stanko Srcic
IPC分类号： A61K9/48 , B29B9/00 , A61K9/14 , A61K31/192 , A61K9/20
CPC分类号： A61K9/1641 , A61K9/1694 , A61K31/192
摘要： The present invention provides a method of making solid micropellets of which at least 75% by weight have a diameter less than 500 μm comprising (i) melting one or more binders; and (ii) combining the one or more binders melted in step (i) with a pharmaceutically active ingredient to form solid micropellets. Solid micropellets obtainable by this method are also provided. The invention has particular utility for improving the solubility of poorly water-soluble pharmaceutically active ingredients.
摘要翻译： 本发明提供一种制备其至少75重量％的直径小于500μm的固体微丸的方法，包括（i）熔融一种或多种粘合剂; 和（ii）将步骤（i）中熔化的一种或多种粘合剂与药物活性成分组合以形成固体微丸。 还提供了可通过该方法获得的固体微丸。 本发明特别用于改善水溶性差的药物活性成分的溶解性。
-
10.发明申请GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM COMPRISING N-(2-(2- PHTHALIMIDOETHOXY)-ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK-423) 审中-公开包含N-（2-（2-羟基乙酰氧基） - 乙酰基）-L-氨基-D-谷氨酰胺（LK-423）的胃肠药物剂型公开(公告)号：US20100183714A1
公开(公告)日：2010-07-22
申请号：US10599289
申请日：2005-03-24
申请人： Marija Bogataj , Ales Mrhar , Anton Lavric , Manica Cerne , Doris Tibaut , Anton Stalc , Uros Urleb , Tatjana Mateovic , Greta Cof , Janez Kerc , Rok Dreu , Fumio Yoneda , Shizuko Muraoka
发明人： Marija Bogataj , Ales Mrhar , Anton Lavric , Manica Cerne , Doris Tibaut , Anton Stalc , Uros Urleb , Tatjana Mateovic , Greta Cof , Janez Kerc , Rok Dreu , Fumio Yoneda , Shizuko Muraoka
IPC分类号： A61K9/36 , C07D209/48 , A61K9/14 , A61K38/05 , A61K9/16 , A61K9/50 , A61K9/28 , A61K9/48 , A61K9/32 , A61P1/04 , A61P1/00 , A61P29/00
CPC分类号： A61K9/5073 , A61K9/2095
摘要： The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.
摘要翻译： 本发明涉及能够将活性物质受控和/或定向递送到人或动物的所选择的胃肠道区域的药物剂型。 药物剂型优选包含活性物质N-（2（2-苯二酰亚氨基乙氧基） - 乙酰基）-L-丙氨酰-D-谷氨酸（命名为LK 423）。 公开了通过使用本发明的药物剂型治疗人和/或动物的胃肠道的慢性炎性疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.017 秒)
